XML 17 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenues      
Research and development $ 12,268,960 $ 14,987,628 $ 8,175,878
Operating expenses      
Selling, general and administrative 12,303,050 13,713,635 10,582,068
Research and development 16,679,712 19,710,673 13,130,529
Patent expenses 909,946 909,376 1,009,053
Litigation expense 0 0 14,407,494
Lease termination 1,225,421 0 0
Interest on PharmAthene liability 0 11,668,900 0
Total operating expenses 31,118,129 46,002,584 39,129,144
Operating loss (18,849,169) (31,014,956) (30,953,266)
Interest expense 14,758,140 2,395,517 266,726
Loss from increase in fair value of warrant liability 4,738,753 894,785 0
Backstop fee 0 (1,764,240) 0
Other income, net 16,788 102,324 42,202
Reorganization items, net 0 (3,716,902) (7,811,551)
Loss before income taxes (38,329,274) (39,684,076) (38,989,341)
Benefit/(Provision) for income taxes 2,093,790 (13,884) (461,983)
Net and comprehensive loss $ (36,235,484) $ (39,697,960) $ (39,451,324)
Earnings (loss) per share: basic and diluted (usd per share) $ (0.46) $ (0.69) $ (0.73)
Weighted average shares outstanding: basic and diluted (in shares) 78,874,494 57,188,503 53,777,687